+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Neuroprotection Market by Product, Treatment, Route of Administration, Application, End Users - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 183 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 4857892
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Neuroprotection Market grew from USD 290.98 billion in 2023 to USD 311.79 billion in 2024. It is expected to continue growing at a CAGR of 7.63%, reaching USD 486.89 billion by 2030.

Neuroprotection refers to the strategies and mechanisms involved in preventing neuronal damage and degeneration across various neurological disorders, including Alzheimer's, Parkinson's, and multiple sclerosis. The necessity for neuroprotection arises from the increasing prevalence of neurodegenerative diseases, driven by aging populations worldwide. It finds applications in pharmaceuticals, biotechnology, and medical devices aimed at minimizing neuronal injury and preserving neurological function. End-use sectors primarily encompass healthcare institutions, research organizations, and pharmaceuticals. Key factors influencing growth include advancements in medical research, increased funding for neurological disorder research, and rising demand for effective disease-modifying therapies. Additionally, the potential growth in the market is propelled by increasing collaborations between biotech firms and government institutions, development of biomarkers, and personalized medicine approaches. Current opportunities lie in leveraging artificial intelligence for drug discovery, enhancing clinical trial efficiencies, and exploring novel small molecules and biologics for neuroprotection. However, limitations and challenges include stringent regulatory environments, high R&D costs, and potential side effects associated with neuroprotective agents. Moreover, the complexity of the central nervous system poses significant hurdles in translating research into effective therapies. Areas ripe for innovation include exploring gene therapy, neuroinformatics, and regenerative medicine approaches such as stem cell therapy. There's also potential in developing non-invasive neuroprotective interventions like diet and lifestyle modifications. The market exhibits a dynamic nature with a mix of well-established pharmaceutical giants and emerging biotech companies, leading to competitive and collaborative research landscapes. Companies should focus on strategic partnerships, enhancing R&D capabilities, and tapping into emerging markets to optimize growth opportunities. Emphasis on personalized treatment and early diagnosis through advanced imaging and biomarkers remains crucial to sway the market momentum favorably.

Understanding Market Dynamics in the Neuroprotection Market

The Neuroprotection Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Rising prevalence of neurodegenerative diseases increasing the need for neuroprotective therapies
    • Growing focus on preventive healthcare and lifestyle changes to reduce risk factors
    • Increased awareness among healthcare professionals and patients about neurological conditions
  • Market Restraints
    • Complexity of blood-brain barrier limiting delivery and efficacy of neuroprotective agents
  • Market Opportunities
    • Increasing investments in R&D for the development of non-invasive and preventive neuroprotective strategies
    • Development of personalized neuroprotective therapies and customizable treatment plans
  • Market Challenges
    • Stringent regulatory requirements hindering the development and approval of neuroprotective therapies

Exploring Porter’s Five Forces for the Neuroprotection Market

Porter’s Five Forces framework further strengthens the insights of the Neuroprotection Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Neuroprotection Market

External macro-environmental factors deeply influence the performance of the Neuroprotection Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Neuroprotection Market

The Neuroprotection Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Neuroprotection Market

The Neuroprotection Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Neuroprotection Market

The Neuroprotection Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Neuroprotection Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Abcam PLC by Danaher Corporation, Anavex Life Sciences corp., AstraZeneca PLC, Astrocyte Pharmaceuticals Inc., Bayer AG, Biogen Inc., Bristol Myers Squibb Company (BMS)., Daiichi Sankyo Company, Limited, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Ionis Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Neuren Pharmaceuticals, Novartis AG, Pfizer Inc., Reata Pharmaceuticals, Inc., Sage Therapeutics, Inc., Sangamo Therapeutics, Inc., Sanofi S.A., Sunovion Pharmaceuticals Inc, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Neuroprotection Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Product
    • Apoptosis Inhibitors
    • Free Anti-Inflammatory Agents
    • Glutamate Antagonists
    • Metal Ion Chelators
    • Neurotrophic Factors
    • Radical Trapping Agents
    • Stimulants
  • Treatment
    • Alzheimer's Disease
    • Amyotrophic Lateral Sclerosis
    • Brain Injury
    • Huntington's Disease
    • Multiple Sclerosis
    • Neuropathies
    • Ocular Degeneration
    • Parkinson's Disease
  • Route of Administration
    • Intrathecal
    • Intravenous
    • Oral
    • Transdermal
  • Application
    • Prevention
    • Treatment
  • End Users
    • Academic & Research Institutes
    • Clinics
    • Hospitals
    • Pharmaceutical & Biotechnology Companies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of neurodegenerative diseases increasing the need for neuroprotective therapies
5.1.1.2. Growing focus on preventive healthcare and lifestyle changes to reduce risk factors
5.1.1.3. Increased awareness among healthcare professionals and patients about neurological conditions
5.1.2. Restraints
5.1.2.1. Complexity of blood-brain barrier limiting delivery and efficacy of neuroprotective agents
5.1.3. Opportunities
5.1.3.1. Increasing investments in R&D for the development of non-invasive and preventive neuroprotective strategies
5.1.3.2. Development of personalized neuroprotective therapies and customizable treatment plans
5.1.4. Challenges
5.1.4.1. Stringent regulatory requirements hindering the development and approval of neuroprotective therapies
5.2. Market Segmentation Analysis
5.2.1. Product: Growing utilization of apoptosis inhibitors to maintain neuronal survival and prevent the progression of neurodegeneration
5.2.2. Application: Growing preference for prevention of neuroprotection among health-conscious consumers
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Neuroprotection Market, by Product
6.1. Introduction
6.2. Apoptosis Inhibitors
6.3. Free Anti-Inflammatory Agents
6.4. Glutamate Antagonists
6.5. Metal Ion Chelators
6.6. Neurotrophic Factors
6.7. Radical Trapping Agents
6.8. Stimulants
7. Neuroprotection Market, by Treatment
7.1. Introduction
7.2. Alzheimer's Disease
7.3. Amyotrophic Lateral Sclerosis
7.4. Brain Injury
7.5. Huntington's Disease
7.6. Multiple Sclerosis
7.7. Neuropathies
7.8. Ocular Degeneration
7.9. Parkinson's Disease
8. Neuroprotection Market, by Route of Administration
8.1. Introduction
8.2. Intrathecal
8.3. Intravenous
8.4. Oral
8.5. Transdermal
9. Neuroprotection Market, by Application
9.1. Introduction
9.2. Prevention
9.3. Treatment
10. Neuroprotection Market, by End Users
10.1. Introduction
10.2. Academic & Research Institutes
10.3. Clinics
10.4. Hospitals
10.5. Pharmaceutical & Biotechnology Companies
11. Americas Neuroprotection Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Neuroprotection Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Neuroprotection Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.3.1. Boston Scientific to enhance neurovascular portfolio with Silk Road Medical acquisition for cutting-edge TCAR technology
14.3.2. Silk Road Medical's introduction of the Enroute plus transcarotid system emphasizing neuroprotection
14.3.3. Astrocyte Pharmaceuticals moves forward with AST-004 as it enters phase 2 trials for ischemic stroke treatment
14.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. NEUROPROTECTION MARKET RESEARCH PROCESS
FIGURE 2. NEUROPROTECTION MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL NEUROPROTECTION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL NEUROPROTECTION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 7. GLOBAL NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
FIGURE 9. GLOBAL NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 11. GLOBAL NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 13. GLOBAL NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL NEUROPROTECTION MARKET SIZE, BY END USERS, 2023 VS 2030 (%)
FIGURE 15. GLOBAL NEUROPROTECTION MARKET SIZE, BY END USERS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. AMERICAS NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. AMERICAS NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. UNITED STATES NEUROPROTECTION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 19. UNITED STATES NEUROPROTECTION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. NEUROPROTECTION MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 25. NEUROPROTECTION MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. NEUROPROTECTION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL NEUROPROTECTION MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL NEUROPROTECTION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. NEUROPROTECTION MARKET DYNAMICS
TABLE 7. GLOBAL NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL NEUROPROTECTION MARKET SIZE, BY APOPTOSIS INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL NEUROPROTECTION MARKET SIZE, BY FREE ANTI-INFLAMMATORY AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL NEUROPROTECTION MARKET SIZE, BY GLUTAMATE ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL NEUROPROTECTION MARKET SIZE, BY METAL ION CHELATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL NEUROPROTECTION MARKET SIZE, BY NEUROTROPHIC FACTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL NEUROPROTECTION MARKET SIZE, BY RADICAL TRAPPING AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL NEUROPROTECTION MARKET SIZE, BY STIMULANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL NEUROPROTECTION MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL NEUROPROTECTION MARKET SIZE, BY BRAIN INJURY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL NEUROPROTECTION MARKET SIZE, BY HUNTINGTON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL NEUROPROTECTION MARKET SIZE, BY NEUROPATHIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL NEUROPROTECTION MARKET SIZE, BY OCULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL NEUROPROTECTION MARKET SIZE, BY INTRATHECAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL NEUROPROTECTION MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL NEUROPROTECTION MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL NEUROPROTECTION MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL NEUROPROTECTION MARKET SIZE, BY PREVENTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL NEUROPROTECTION MARKET SIZE, BY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL NEUROPROTECTION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL NEUROPROTECTION MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL NEUROPROTECTION MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 43. ARGENTINA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 46. ARGENTINA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 47. ARGENTINA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 48. BRAZIL NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 49. BRAZIL NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 51. BRAZIL NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 52. BRAZIL NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 53. CANADA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 54. CANADA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 55. CANADA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 56. CANADA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 57. CANADA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 58. MEXICO NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 59. MEXICO NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 60. MEXICO NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 61. MEXICO NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 62. MEXICO NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES NEUROPROTECTION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 69. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 70. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 71. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 72. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 73. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 74. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 75. AUSTRALIA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 76. AUSTRALIA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 77. AUSTRALIA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 78. AUSTRALIA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 79. AUSTRALIA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 80. CHINA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 81. CHINA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 82. CHINA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. CHINA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 84. CHINA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 85. INDIA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 86. INDIA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 87. INDIA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. INDIA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 89. INDIA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 90. INDONESIA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 91. INDONESIA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 92. INDONESIA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. INDONESIA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 94. INDONESIA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 95. JAPAN NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 96. JAPAN NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 97. JAPAN NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. JAPAN NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 99. JAPAN NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 100. MALAYSIA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 101. MALAYSIA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 102. MALAYSIA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 103. MALAYSIA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 104. MALAYSIA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 105. PHILIPPINES NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 106. PHILIPPINES NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 107. PHILIPPINES NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. PHILIPPINES NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 109. PHILIPPINES NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 110. SINGAPORE NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 111. SINGAPORE NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 112. SINGAPORE NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 113. SINGAPORE NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 114. SINGAPORE NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 115. SOUTH KOREA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 116. SOUTH KOREA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 117. SOUTH KOREA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 118. SOUTH KOREA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 119. SOUTH KOREA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 120. TAIWAN NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 121. TAIWAN NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 122. TAIWAN NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. TAIWAN NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 124. TAIWAN NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 125. THAILAND NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 126. THAILAND NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 127. THAILAND NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 128. THAILAND NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 129. THAILAND NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 130. VIETNAM NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 131. VIETNAM NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 132. VIETNAM NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 133. VIETNAM NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 134. VIETNAM NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 141. DENMARK NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 142. DENMARK NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 143. DENMARK NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 144. DENMARK NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 145. DENMARK NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 146. EGYPT NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 147. EGYPT NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 148. EGYPT NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 149. EGYPT NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 150. EGYPT NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 151. FINLAND NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 152. FINLAND NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 153. FINLAND NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. FINLAND NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 155. FINLAND NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 156. FRANCE NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 157. FRANCE NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 158. FRANCE NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 159. FRANCE NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 160. FRANCE NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 161. GERMANY NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 162. GERMANY NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 163. GERMANY NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 164. GERMANY NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 165. GERMANY NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 166. ISRAEL NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 167. ISRAEL NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 168. ISRAEL NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 169. ISRAEL NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 170. ISRAEL NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 171. ITALY NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 172. ITALY NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 173. ITALY NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 174. ITALY NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 175. ITALY NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 176. NETHERLANDS NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 177. NETHERLANDS NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 178. NETHERLANDS NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. NETHERLANDS NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 180. NETHERLANDS NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 181. NIGERIA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 182. NIGERIA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 183. NIGERIA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 184. NIGERIA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 185. NIGERIA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 186. NORWAY NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 187. NORWAY NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 188. NORWAY NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 189. NORWAY NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 190. NORWAY NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 191. POLAND NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 192. POLAND NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 193. POLAND NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 194. POLAND NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 195. POLAND NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 196. QATAR NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 197. QATAR NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 198. QATAR NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 199. QATAR NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 200. QATAR NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 201. RUSSIA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 202. RUSSIA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 203. RUSSIA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 204. RUSSIA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 205. RUSSIA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 206. SAUDI ARABIA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 207. SAUDI ARABIA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 208. SAUDI ARABIA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 209. SAUDI ARABIA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 210. SAUDI ARABIA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 211. SOUTH AFRICA NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 212. SOUTH AFRICA NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 213. SOUTH AFRICA NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 214. SOUTH AFRICA NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 215. SOUTH AFRICA NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 216. SPAIN NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 217. SPAIN NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 218. SPAIN NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 219. SPAIN NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 220. SPAIN NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 221. SWEDEN NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 222. SWEDEN NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 223. SWEDEN NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 224. SWEDEN NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 225. SWEDEN NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 226. SWITZERLAND NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 227. SWITZERLAND NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 228. SWITZERLAND NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 229. SWITZERLAND NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 230. SWITZERLAND NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 231. TURKEY NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 232. TURKEY NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 233. TURKEY NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 234. TURKEY NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 235. TURKEY NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 236. UNITED ARAB EMIRATES NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 237. UNITED ARAB EMIRATES NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 238. UNITED ARAB EMIRATES NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 239. UNITED ARAB EMIRATES NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 240. UNITED ARAB EMIRATES NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 241. UNITED KINGDOM NEUROPROTECTION MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 242. UNITED KINGDOM NEUROPROTECTION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 243. UNITED KINGDOM NEUROPROTECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 244. UNITED KINGDOM NEUROPROTECTION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 245. UNITED KINGDOM NEUROPROTECTION MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 246. NEUROPROTECTION MARKET SHARE, BY KEY PLAYER, 2023
TABLE 247. NEUROPROTECTION MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Neuroprotection market, which are profiled in this report, include:
  • AbbVie Inc.
  • Abcam PLC by Danaher Corporation
  • Anavex Life Sciences corp.
  • AstraZeneca PLC
  • Astrocyte Pharmaceuticals Inc.
  • Bayer AG
  • Biogen Inc.
  • Bristol Myers Squibb Company (BMS).
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Neuren Pharmaceuticals
  • Novartis AG
  • Pfizer Inc.
  • Reata Pharmaceuticals, Inc.
  • Sage Therapeutics, Inc.
  • Sangamo Therapeutics, Inc.
  • Sanofi S.A.
  • Sunovion Pharmaceuticals Inc
  • Teva Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...

Table Information